Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
YABRO® (aerosolized Sodium Hyaluronate) - Medical Device for the Restoration and Maintenance of the Mucous Membranes and Respiratory Tract Tissue Physiological Conditions
IBSA Institut Biochimique SA Switzerland flag Switzerland
Abstract ID:
Yabro®, a 0,3% hyaluronic acid solution for aerosol therapy, is indicated for the restoration and maintenance of physiological conditions of the mucous membranes in upper and lower respiratory tract diseases...
Contact Alessandro Ferri
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
Endonasal use of sodium hyaluronate improve both mucociliary clearance and the regeneration of the epithelium of nasal mucosa as a consequence of a more rapid recovery of the impaired ciliated cells.

Yabro ® is a Class IIa medical device intended for the restoration and maintenance of the physiological conditions of the interstice and the pulmonary mucosa which have been impaired in chronic bronchial inflammation, for example in asthma and chronic obstructive pulmonary disease (COPD).Yabro ® is also indicated for the adjuvant treatment of upper respiratory disease such as tonsillitis, laryngitis, pharyngitis, nasopharyngitis, sinusitis, rhinitis, tracheitis, both in acute and chronic hoarseness, vocal cord inflammation with and without dysphonia; to improve post-operative conditions of the nasal mucosa after intranasal operations. Each Yabro ® vial to be administered by aerosol one per day contains 0.3% of hyaluronic acid sodium salt in 3 ml of an isotonic solution.


When YABRO ® is proposed for the treatment of upper respiratory disease, the solution can also be administered by using the innovative device YABRO ® Spray-sol.


YABRO ® Spray-sol enables an easy nebulization of YABRO ® solution into the nostril. It offers equal effectiveness of traditional nebulizers with the advantage of a more comfortable and practical use for the patient.


GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Pharmaceutical company with a respiratory treatments portfolio interested in in-licensing YABRO®, a 0,3% hyaluronic acid solution for aerosol therapy, indicated for the restoration and maintenance of physiological conditions of the mucous membranes in upper and lower respiratory tract diseases.
FEATURED
Last Updated Aug 2016
Technology Type MEDICAL DEVICE
Phase of Development REGISTERED / FINISHED PRODUCT
PRIVATE INSTITUTE